Collegium Pharmaceutical (NASDAQ:COLL) Now Covered by Needham & Company LLC

Share on StockTwits

Needham & Company LLC initiated coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report released on Friday, TipRanks reports. The brokerage issued a buy rating and a $36.00 price target on the specialty pharmaceutical company’s stock.

COLL has been the subject of a number of other research reports. BidaskClub cut Collegium Pharmaceutical from a hold rating to a sell rating in a research report on Tuesday, June 9th. Guggenheim initiated coverage on Collegium Pharmaceutical in a report on Tuesday, May 26th. They issued a neutral rating for the company. Zacks Investment Research lowered Collegium Pharmaceutical from a hold rating to a sell rating in a research note on Wednesday, April 29th. Finally, William Blair reaffirmed a buy rating on shares of Collegium Pharmaceutical in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. Collegium Pharmaceutical has an average rating of Hold and a consensus price target of $31.43.

Shares of NASDAQ COLL opened at $17.14 on Friday. The company has a debt-to-equity ratio of 1.77, a current ratio of 0.92 and a quick ratio of 0.85. The stock has a market capitalization of $585.50 million, a P/E ratio of -45.11, a price-to-earnings-growth ratio of 0.51 and a beta of 1.07. Collegium Pharmaceutical has a 1-year low of $10.01 and a 1-year high of $25.59. The business has a fifty day moving average price of $20.09 and a 200 day moving average price of $20.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, missing the Zacks’ consensus estimate of $0.66 by ($0.65). The firm had revenue of $76.51 million during the quarter, compared to the consensus estimate of $76.64 million. Collegium Pharmaceutical had a negative return on equity of 12.62% and a negative net margin of 4.21%. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. As a group, equities research analysts anticipate that Collegium Pharmaceutical will post 1.6 earnings per share for the current fiscal year.

In other Collegium Pharmaceutical news, CEO Joseph Ciaffoni sold 70,676 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $21.53, for a total value of $1,521,654.28. Following the sale, the chief executive officer now directly owns 204,515 shares of the company’s stock, valued at $4,403,207.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael Thomas Heffernan sold 19,254 shares of Collegium Pharmaceutical stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $21.63, for a total transaction of $416,464.02. Following the completion of the sale, the director now directly owns 99,670 shares in the company, valued at approximately $2,155,862.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 102,353 shares of company stock worth $2,211,493. Insiders own 8.08% of the company’s stock.

Several institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its stake in Collegium Pharmaceutical by 13.4% during the 1st quarter. Janus Henderson Group PLC now owns 5,103,966 shares of the specialty pharmaceutical company’s stock worth $83,347,000 after purchasing an additional 601,617 shares during the last quarter. Camber Capital Management LP purchased a new position in shares of Collegium Pharmaceutical in the first quarter worth about $32,660,000. Franklin Resources Inc. boosted its position in Collegium Pharmaceutical by 3.4% during the first quarter. Franklin Resources Inc. now owns 1,829,772 shares of the specialty pharmaceutical company’s stock worth $29,881,000 after acquiring an additional 59,620 shares during the last quarter. Perceptive Advisors LLC boosted its position in Collegium Pharmaceutical by 268.3% during the first quarter. Perceptive Advisors LLC now owns 1,551,722 shares of the specialty pharmaceutical company’s stock worth $25,339,000 after acquiring an additional 1,130,450 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in Collegium Pharmaceutical by 67.6% during the 4th quarter. Renaissance Technologies LLC now owns 1,252,328 shares of the specialty pharmaceutical company’s stock valued at $25,773,000 after acquiring an additional 505,128 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Recommended Story: New Google Finance Tool and Screening Stocks

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.